TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immunotherapy using PD-1/PD-L1 checkpoint inhibitors has advanced cancer treatment but faces challenges like low response rates and drug resistance.
• Tumor cell PD-L1 expression levels are linked to treatment response, highlighting the need to identify regulators of PD-L1 expression and stability.
• Targeting molecular pathways controlling PD-L1 is crucial for improving immune checkpoint therapies.

Purpose of the Study:

• To identify novel molecular targets that positively modulate programmed cell death-ligand 1 (PD-L1) expression in melanoma cells.
• To elucidate the mechanism by which TRAF6 regulates PD-L1 expression and its downstream signaling pathways.
• To evaluate the therapeutic potential of inhibiting TRAF6 for enhancing anti-tumor immunity.

Main Methods:

• Conducted a Stress and Proteostasis CRISPR interference screen to identify PD-L1 positive modulators.
• Utilized in vitro and in vivo assays to investigate the function and mechanism of TRAF6 and its downstream YAP1/TFCP2 signaling in melanoma.
• Assessed the effect of TRAF6 inhibition using Bortezomib on PD-L1 expression and CD8+ T cell activity.

Main Results:

• Identified TRAF6 (E3 ubiquitin ligase) as a critical regulator of PD-L1 in melanoma cells.
• Demonstrated that TRAF6 stabilizes YAP1 via K63 poly-ubiquitination, promoting YAP1/TFCP2 complex formation and subsequent PD-L1 transcription.
• Showed that Bortezomib inhibition of TRAF6 reduces PD-L1, enhances CD8+ T cell cytolytic activity, and improves anti-tumor immunity comparably to anti-PD-1 therapy without significant toxicity.

Conclusions:

• TRAF6 plays a significant role in regulating PD-L1 expression and stability in melanoma through the YAP1/TFCP2 pathway.
• Inhibition of TRAF6 presents a promising strategy to enhance endogenous anti-tumor immunity by reducing PD-L1 expression.
• Targeting TRAF6 could offer a novel therapeutic approach for cancers overexpressing TRAF6 and PD-L1.